RxDoctor Payments Data

Lila Bennett

Family · Valdosta, GANPI 1932620598

Payments from drug & device makers

$9,126in general payments, 2019–2025

Across 302 payments — averaging $30.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Novartis$915
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$825
  • Johnson & Johnson$752
  • E.r. Squibb & Sons, L.L.C.$677
  • Boehringer Ingelheim$562
  • plus $2K from 15 others

What the payments were for

  • Travel & lodging$2,60629%
  • Food & beverage$6,52071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,126 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$14,082
Medicare patients
133
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$53,868
JardianceEmpagliflozin36$37,999
XareltoRivaroxaban28$26,306
EntrestoSacubitril/Valsartan30$24,888
Repatha SureclickEvolocumab12$7,420
Atorvastatin Calcium139$919
Losartan Potassium135$761
Metoprolol Succinate75$581
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$459
Valsartan28$448
Amlodipine Besylate83$360
ClopidogrelClopidogrel Bisulfate47$354
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav45$325
Spironolactone55$321
Amiodarone Hcl13$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$53,86872 claims
Boehringer IngelheimJardiance$562$37,99936 claims
Johnson & JohnsonXarelto$752$26,30628 claims
NovartisEntresto$915$24,88830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →